COMMUNICATION WITH SHAREHOLDERS
Pursuant to Article 5(5) of the Law of 15 September 2000 Commercial Companies Code (Journal of Laws of 2000, No. 94, item 1037, as further amended) in the wording in force from 1 January 2020, on the basis of the amendment made by the Act of 30 August 2019 amending the Commercial Companies Code and certain other acts (Journal of Laws of 2019, item 1798), a joint stock company is obliged to maintain its own website and also to place on this website, in places designated for communication with shareholders, the announcements required by law or by the statute from the company.
CHANGES IN THE MANAGEMENT BOARD OF HELIX IMMUNO-ONCOLOGY S.A.
On 4 June 2020, the Extraordinary General Meeting of HELIX IMMUNO-ONCOLOGY S.A.adopted resolutions on the
changes in the Company's Management Board, entrusting the role of the President of the Management Board as of 5
June 2020 to Mr. Ireneusz Fąfara and the role of the Vice-President of the Management Board to Mr. Paweł Wiśniewski.
Since 5 June 2020, the Company's Management Board has been composed of two members, as follows:
1.Ireneusz Fąfara - President of the Management Board
2. Paweł Wiśniewski - Vice-President of the Management Board
SUBMITTING DOCUMENTS TO THE FINANCIAL DOCUMENTS REPOSITORY
On 5 February 2020, HELIX IMMUNO-ONCOLOGY S.A. submitted the following documents for the financial year from
1 August 2018 to 31 July 2019 to the Financial Documents Repository:
1. the financial statements,
2. the Management Board’s report on company activity,
3. the auditor's opinion / audit report on the annual financial statements,
4. the resolution on profit distribution or loss coverage,
5. the resolution to approve the financial statements.
ABOUT THE COMPANY
HELIX IMMUNO-ONCOLOGY S.A. is a subsidiary of Helix BioPharma Corp. The shares of Helix BioPharma Corp. are
currently listed on the Toronto Stock Exchange (TSX) under the symbol "HBP". HELIX IMMUNO-ONCOLOGY S.A.
completed the process of transformation from a limited liability company into a joint stock company in 2017. This is
the first step on the way to the company's debut on the Warsaw Stock Exchange.
HELIX IMMUNO-ONCOLOGY S.A. actively works on developing innovative products used in cancer therapy. The
company's activities in developing potential drugs are based on a technological platform: Tumour Defence Breaker
(DOS47), and in particular works on the development of the V-DOS47 molecule, which is used to treat breast
cancer and other solid cancers.
HELIX IMMUNO-ONCOLOGY S.A.
Bojkowska 59C Street
share capital: 1,101,950.00 PLN
District Court in Gliwice
10th Economic Department of the National Court Register
THE MANAGEMENT BOARD
Ireneusz Fąfara – President of the Management Board
Dr Paweł Wiśniewski - Vice-President of the Management Board
Prof. Sławomir Majewski - Chairman of the Supervisory Board
Dr Heman Chao - Member of the Supervisory Board
Andreas Kandziora - Member of the Supervisory Board
Contact for investors:
Paweł Wiśniewski – Vice-President of the Management Board